(Q48820657)

15 February 2018

title

Design of potent and selective in vivo antagonists of the neurohypophysial peptides. (English)

1 reference

15 February 2018

2

Sawyer WH

1 reference

15 February 2018

author name string

Manning M

series ordinal

1

1 reference

15 February 2018

publication date

1 January 1983

1 reference

15 February 2018

Progress in Brain Research

published in

1 reference

15 February 2018

volume

60

1 reference

15 February 2018

page(s)

367-382

1 reference

15 February 2018

Vascular effects of arginine vasopressin during fluid deprivation in the rat.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Relative contributions of arginine vasopressin and angiotensin II to maintenance of systemic arterial pressure in the anesthetized water-deprived rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Design of potent antagonists of the vasopressor response to arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Design and synthesis of potent in vivo antagonists of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

The syndrome of inappropriate secretion of antidiuretic hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Role of vasopressin in abnormal water excretion in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Synthetic I-N-Carbamylhemicystine-2-O-methyltyrosine-oxytocin (N-Carbamyl-O-methyl-oxytocin): a Specific Antagonist to the Actions of Oxytocin and Vasopressin on the Uterus and Mammary Gland

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Some pharmacological properties of a synthetic oxytocin analogue [1-N-carbamoyl-hemicystine-2-O-methyltyrosine]-oxytocin (carbamoyl-methyloxytocin), an antagonist to the neurohypophysial hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Destruction of Noradrenergic Neurons in Rabbit Brainstem Elevates Plasma Vasopressin, Causing Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

4-Leucine-Oxytocin: Natriuretic, Diuretic, and Antivasopressin Polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Evidence and quantification of the vasopressin arterial pressure control system in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

The Synthesis of Oxytocin1

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

(1-Beta-mercapto-beta,beta-diethylpropionic acid)-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Role of vasopressin in cardiovascular homeostasis and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

The action of 2-O-Methyltyrosine-oxytocin on the rat and rabbit uterus: effect of some experimental conditions on change from agonism to antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response t

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Synthesis of O-alkylated lysine-vasopressins, inhibitors of the antidiuretic response to lysine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Vasopressor receptor antagonist prevents behavioural effects of vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Is vasopressin an important hypertensive hormone?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

1-(.beta.-Mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid),4-valine, 8-D-argininevasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Synthetic antagonists of in vivo responses by the rat uterus to oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Antagonists of vasopressor and antidiuretic responses to arginine vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Solid phase synthesis of (1-deamino,4-valine)-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

1-Deaminopenicillamine,4-threonineoxytocin, a potent inhibitor of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Design of potent and selective antagonists of the vasopressor responses to arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

4-Phenylalanineoxytocin, an inhibitor of the antidiuretic effect of 8-arginine-vasopressin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

1-.beta.-Mercapto-.beta.,.beta.-pentamethylenepropionic acidoxytocin, a potent inhibitor of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

The release of vasopressin in response to haemorrhage and its role in the mechanism of blood pressure regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Structural Changes in the Arginine Vasopressin Molecule that Enhance Antidiuretic Activity and Specificity1

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Neurohypophysial peptides design of tissue-specific agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

pA, a new scale for the measurement of drug antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

Synthesis of three oxytocin analogs related to [1-deaminopenicillamine]oxytocin prossessing antioxytocic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964404-0

7 January 2021

10.1016/S0079-6123(08)64404-0

Identifiers

DOI

0 references

PubMed ID

6665151

1 reference

15 February 2018